PulmonoVac® is a platform vaccine technology in which a viral target antigen is combined with Nexavant and delivered to the lung for the induction of lung-resident memory CD4+ T-cells for a broad spectrum of cross-reactive protection. The principal has been proven against influenza, which is notorious for its frequent mutations. PulmonoVac establishes a scientific basis for upgrading to a broad-spectrum viral vaccine by simply mixing Nexavant with corresponding antigens and changing the route of administration. PulmonoVac also can induce the same lung T–cell response by boosting shots for the conventional intramuscular vaccinees.